Next Article in Journal
Regulation of Melanocortin-3 and -4 Receptors by Isoforms of Melanocortin-2 Receptor Accessory Protein 1 and 2
Previous Article in Journal
Role of EPA in Inflammation: Mechanisms, Effects, and Clinical Relevance
Previous Article in Special Issue
Dopamine D3 Receptor: Contemporary Views of Its Function and Pharmacology for Neuropsychiatric Diseases
Review

Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease

1
Différenciation et Communication Neuroendocrine, Endocrine et Germinale Laboratory, Institute for Research and Innovation in Biomedicine of Normandy (IRIB), University of Rouen, INSERM 1239, 76000 Rouen, France
2
Department of Medical Biochemistry, Rouen University Hospital, 76000 Rouen, France
3
Laboratory of Neurophysiology, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, 2080 Msida, Malta
4
Neuroscience Division, School of Biosciences, Cardiff University, Cardiff CF10 3AT, UK
5
Unité Mixte de Recherche (UMR) 5287, Centre National de la Recherche Scientifique (CNRS), CEDEX, 33000 Bordeaux, France
*
Author to whom correspondence should be addressed.
Academic Editor: Prakash Kulkarni
Biomolecules 2022, 12(2), 243; https://doi.org/10.3390/biom12020243
Received: 29 December 2021 / Revised: 19 January 2022 / Accepted: 26 January 2022 / Published: 1 February 2022
The discovery of the D3 receptor (D3R) subtypes of dopamine (DA) has generated an understandable increase in interest in the field of neurological diseases, especially Parkinson’s disease (PD). Indeed, although DA replacement therapy with l-DOPA has provided an effective treatment for patients with PD, it is responsible for invalidating abnormal involuntary movements, known as L-DOPA-induced dyskinesia, which constitutes a serious limitation of the use of this therapy. Of particular interest is the finding that chronic l-DOPA treatment can trigger the expression of D1R–D3R heteromeric interactions in the dorsal striatum. The D3R is expressed in various tissues of the central nervous system, including the striatum. Compelling research has focused on striatal D3Rs in the context of PD and motor side effects, including dyskinesia, occurring with DA replacement therapy. Therefore, this review will briefly describe the basal ganglia (BG) and the DA transmission within these brain regions, before going into more detail with regard to the role of D3Rs in PD and their participation in the current treatments. Numerous studies have also highlighted specific interactions between D1Rs and D3Rs that could promote dyskinesia. Finally, this review will also address the possibility that D3Rs located outside of the BG may mediate some of the effects of DA replacement therapy. View Full-Text
Keywords: DA replacement therapy; D1R–D3R heteromer; l-DOPA; pharmacology; basal ganglia; neurobiology; dyskinesias DA replacement therapy; D1R–D3R heteromer; l-DOPA; pharmacology; basal ganglia; neurobiology; dyskinesias
Show Figures

Figure 1

MDPI and ACS Style

Chagraoui, A.; Di Giovanni, G.; De Deurwaerdère, P. Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease. Biomolecules 2022, 12, 243. https://doi.org/10.3390/biom12020243

AMA Style

Chagraoui A, Di Giovanni G, De Deurwaerdère P. Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease. Biomolecules. 2022; 12(2):243. https://doi.org/10.3390/biom12020243

Chicago/Turabian Style

Chagraoui, Abdeslam, Giuseppe Di Giovanni, and Philippe De Deurwaerdère. 2022. "Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease" Biomolecules 12, no. 2: 243. https://doi.org/10.3390/biom12020243

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop